NCT02078973 (DOVA) is a Phase 2 clinical trial of 15 mg tolvaptan in Nephropathy, sponsored by Regional Hospital Holstebro.

Who is sponsoring NCT02078973?

NCT02078973 is sponsored by Regional Hospital Holstebro.

What drugs are being tested in NCT02078973?

Interventions in NCT02078973: 15 mg tolvaptan, 30 mg tolvaptan, 45 mg tolvaptan, Placebo.

What condition does NCT02078973 study?

NCT02078973 studies Nephropathy.

Is NCT02078973 still recruiting?

NCT02078973 is currently completed. Last updated 28 February 2017.

Last reviewed 2017-02-28 · How we verify

NCT02078973: DOVA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of Tolvaptan on Renal Handling of Water and Sodium, Vasoactive Hormones and Circulatory System, During Basal Conditions and During Inhibition of the Nitric Oxide System in Healthy Subjects. A Dose-response Study.

Completed Phase 2 Last updated 28 February 2017

What this trial tests

Phase 2 trial testing 15 mg tolvaptan in Nephropathy in 15 participants. Completed in 1 January 2016.

Timeline

1 March 2014

Primary endpoint
1 January 2016

1 January 2016

Quick facts

Lead sponsor	Regional Hospital Holstebro
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	15
Start date	1 March 2014
Primary completion	1 January 2016
Estimated completion	1 January 2016
Sites	1 location across Denmark

Drugs / interventions tested

15 mg tolvaptan — full drug profile →
30 mg tolvaptan — full drug profile →
45 mg tolvaptan — full drug profile →
Placebo

Conditions studied

Nephropathy — all drugs for Nephropathy →

Sponsor

Regional Hospital Holstebro

Who can join

Adults 18 to 40, any sex, with Nephropathy. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

CH2O
Time frame: 5-6 Hours
Measurement of H2O clearance at baseline, during and after L-NMMA infusion

Sponsor's own description

Tolvaptan is a selective vasopressin receptor antagonist (V2R) that increases free water and sodium excretion. Inhibition of V2R increases vasopressin concentration in plasma, which stimulates V1-receptors in the vascular bed and may change both central and brachial hemodynamics and plasma concentration of vasoactive hormones. The purpose of the study is to measure the effects of tolvaptan on renal handling of water and sodium, systemic hemodynamics and vasoactive hormones at baseline and during nitric oxide (NO)-inhibition with L-NG-monomethyl-arginine (L-NMMA).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of tolvaptan on renal water and sodium excretion and blood pressure during nitric oxide inhibition: a dose-response study in healthy subjects.
Al Therwani S, Rosenbæk JB, Mose FH, Bech JN, et al · · 2017 · cited 7× · PMID 28288570 · DOI 10.1186/s12882-017-0501-1

Verify or expand the search:

Other recruiting trials for Nephropathy

Currently open trials in the same condition.

NCT06837181 — Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) · recruiting
NCT06469190 — An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropat · EARLY_PHASE1 · recruiting
NCT05839314 — Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy · Phase 4 · recruiting
NCT06325059 — The Role of Renal Progenitors and Polyploid Tubular Cell Response in Glomerular and Tubular Diseases · NA · recruiting
NCT05656261 — APOL1 Genetic Testing in African Americans · recruiting

Other Regional Hospital Holstebro trials

Trials by the same sponsor.

NCT05165823 — The Significance of Sodium Balance and the Value of Salt-blood Test in Identifying Salt Sensitive Patients · NA · completed
NCT04363554 — The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease · NA · completed
NCT06019026 — Five-year Migration Pattern and Bone Mineral Density for the Tri-Lock and Summit Femoral Stems. · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02078973 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Regional Hospital Holstebro
Last refreshed: 28 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02078973.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing